About Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Jazz Pharmaceuticals Plc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments primarily in the areas of sleep medicine, neurology, and hematology. The company is dedicated to addressing significant unmet medical needs by creating therapies that improve patient outcomes and quality of life. Jazz Pharma's portfolio includes a range of pharmaceutical products designed to treat various conditions, with a particular emphasis on disorders related to sleep and central nervous system disorders. Through its research and development initiatives, the company aims to advance the scientific understanding of these conditions and contribute to the broader healthcare landscape. Read More
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly sales. The company raised its full-year revenue outlook and said it is preparing for a potential A
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 15.5% year on year t...
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after market hours. Here’s what to look for. Jazz Pharmaceuticals be...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera’s antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.
Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, mark...
Let’s dig into the relative performance of Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings seaso...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Jazz Pharmaceuticals delivered a first quarter that was met with a positive response from the market, driven largely by strong commercial execution across it...
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong first-qu...
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 19.1% year on year ...
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) announced better-than-expected revenue in Q1 CY2026, with sales up 19.1% year on year to $1.07 billion. ...
